BioSpace News Archive

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Lucy Scientific Discovery Inc. Nasdaq: LSDI today announced the closing of its previously announced initial public offering of 1,875,000 common shares at a public offering price of $4.00 per share, for gross proceeds of approximately $7.5 million before deducting offering expenses.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2022.

Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022.

T2 Biosystems, Inc. announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

Berkeley Lights, Inc., a life sciences tools company, announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023.

Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET).

SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.